New drug cocktail shows promise for rare head and neck cancer
NCT ID NCT07353073
First seen Jan 21, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before and after surgery can improve outcomes for people with a rare type of melanoma in the head and neck area. The trial will enroll 30 adults whose tumors can be surgically removed. The main goal is to see how well the treatment shrinks or eliminates the tumor before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
Conditions
Explore the condition pages connected to this study.